RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyLooks like Matt Coffey has been active in developing a new cancer indication for
the use of reovirus in the treatment of LIVER CANCER with a single injection of pelareorep.
September 24, 2024 - Single Versus Repeated Intravenous Oncolytic Virus Infusions – Implications for Rationalised Scheduling of Therapy in Hepatocellular Carcinoma
Karen J. Scott, Emma West, Rebecca Brownlie, Fay Ismail, Christy Ralph, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson
Results Clinical trial data indicate that a single dose of reovirus is equivalent or superior to repeat doses in achieving: (a) induction of an inflammatory cytokine/chemokine response; (b) peripheral blood immune cell activation; and (c) migration of activated CD8+ CTLs.
Also - Combination therapy of reovirus plus anti-PD-L1, but not anti-PD-1, limited tumour growth and extended survival in vivo
Conclusions A single dose of oncolytic virus is equivalent or superior to multiple consecutive doses in inducing an anti-tumour immune response. Combination immune checkpoint blockade with anti-PD-L1 holds potential to maximise the beneficial effects of a single dose, whilst simultaneously avoiding undesirable toxicities in the background liver in the context of HCC.
.
https://www.medrxiv.org/content/10.1101/2024.09.26.24314049v1